(Submitted for publication March 29, 1954 ; accepted May 14, 1954) During recent years several methods have been introduced for estimating the total volume of circulating erythrocytes by measuring dilution in the blood stream of cells which have been tagged with radioactive phosphorus, iron, or chromium (1) (2) (3) (4) (5) (6) . Values for red cell volume thus obtained may be considered more reliable than indirect estimates based on hematocrit and "plasma volume" as measured with T-1824 or other substances which label plasma proteins, because no error is introduced by the discrepancy between venous (or arterial) and "body" hematocrits (7) (8) (9) . For the same reason, a closer approximation to the true total blood volume is found by adding together red cell and "plasma" volumes, as measured independently, than is found by use of the plasma volume-hematocrit methods (10) .
Erythrocytes may also be labeled with carbon monoxide gas, and this is the basis of methods which have been employed widely to estimate blood volume and total circulating hemoglobin (11) (12) (13) (14) (15) (16) (17) . It has long been suspected that the volume of distribution of carbon monoxide in the body (henceforth to be called "CO-available volume") may be larger than true blood volume, since the gas has affinity for pigments which are located extravascularly, such as myoglobin or non-circulating hemoglobin (11, 18, 19) . Previous work has shown a discrepancy between CO-available volume and blood volume as measured with radioactively tagged cells, both in man (9) and in the dog (18 The difference in magnitude between the reported results in man and dog, and the inadequacies of the methods used in the human experiments, leave the problem open to further exploration. For these reasons, and because the CO method has certain practical advantages for physiologic and clinical work, it seemed desirable to make comparative measurements of the apparent volume of erythrocytes in healthy and diseased human subjects, using simultaneously a CO method which has been employed extensively in this laboratory and a method utilizing Cr51.
MATERIALS AND METHODS
The subjects were six healthy volunteers and 29 hospitalized patients with various diseases (Table I) . Determinations of CO-available volume and of the dilution of radioactively tagged cells were carried out simultaneously as a rule, but occasionally in sequence, during the same forenoon. All subjects had fasted overnight and had been recumbent for a minimum of 30 minutes before procedures were begun.
The method used for estimating CO-available volume has been described fully (14, 15) . Carbon monoxide was delivered into a small, closed system into which the subject rebreathed for 20 minutes, 02 being added as required. Samples of blood taken before and at the end of this period were analyzed for CO by the palladium reduction method (20) . No correction was made for the residual CO in the rebreathing system, since this has been shown to account for an error of not more than 1 per cent of the final result (14) . The CO) where Vd is the volume (ml.) of gas delivered into the rebreathing system, corrected to standard conditions of temperature and pressure, and P is a correction factor for purity of the gas. Cl and Ct, respectively, are the concentrations of CO (in ml. per 100 ml.) in samples of whole venous blood taken before and 20 minutes after delivery of the gas.
The total Cr'-available volume was calculated similarly:
Cr" space (liters) =Am X 50 X V> W where At.. is the activity in counts per second per ml. of the tagged cell suspension, Vt.. is the volume of cell suspension injected, and Ab the counts per second per ml. of the blood samples drawn at the end of the various time periods after delivery of the tagged cells.
The red cell volume (subsequently referred to as Vol. RBC/CO and Vol. RBC/Cr') was obtained by multiplying CO-or Cr51-available space by the hematocrit of the respective sample of whole blood used in each analysis.
RESULTS
The results are summarized in Table I and Figure 1 . Column 9, Table I, lists the apparent Table I.) red cell volumes as determined by the CO method, and column 10, the volumes based on the 20-minute samples in the Cr5l method. The corresponding hematocrits are shown in columns 7 and 8.
As shown in Figure 1 * Subjects are referred to by same numbers as in Table I .
by CO. Variations of this degree would be important in the application of these methods to physiologic and pathologic problems.
DISCUSSION
Whenever the measurement of blood volume or fractions thereof is based on the principle of dilution, two criteria must be satisfied. First, the substance which is introduced as indicator must have reached uniform concentration in the cell mass or plasma occupying all portions of the vascular compartment before the sample to be measured is taken. Second, the substance must not leave the blood stream during the mixing period which precedes the sampling. (In methods for determining "plasma" volume which are in use currently, the second criterion is not satisfied, but it is assumed that loss of the indicator occurs at a constant rate during the entire time required for mixing and for collection of serial samples.)
The first criterion probably is met adequately by both methods under consideration here. It has been demonstrated that with the method used in these experiments, CO gas becomes equilibrated with the blood in less than 20 minutes, and remains at essentially constant concentration in the blood for periods of an hour or more. This occurs with subjects at rest, and also during massive venous congestion of the extremities (15).
In our experience, maximum distribution of Cr51-tagged red cells is also reached in 10 to 20 minutes in both normal and pathologic states, although it has been reported that in rare cases of severe congestive heart failure, longer periods may be required for complete mixing (21, 22) . The results of serial sampling, which was done in each experiment reported here, showed no instance of delayed mixing in our subjects. Table II and Figure 2 give the results of eight representative experiments in which samples were taken 10, 20, 30, and 45 minutes, and 24 hours after introduction of radioactively tagged cells. In every case the concentration of tagged cells in the blood had reached plateau levels within 20 minutes after the injection. Even after 24 hours, when some loss of tagged cells from the circulation was to be expected (5, 6, 22) riods, can be attributed to delayed mixing of the chromium-tagged cells or to failure of these cells to reach portions of the circulatory system which were accessible to CO during the first 20 minutes after delivering either agent into the blood stream.
The discrepancy in results can be attributed more easily to failure of the CO method to fulfill the second criterion stated above. The finding of a CO-available space which is consistently larger than the space which is available to cells labeled with chromium might conceivably be attributed to 1) fixation of CO early in the mixing period by hemoglobin or other compounds which are located elsewhere than in the circulating blood, 2) metabolism or excretion of the CO, or 3) leakage of gas through faulty connections.
The first explanation is the most acceptable one. The characteristics of the time: concentration curve of CO in the blood are not consistent with continuing loss of CO by metabolism or excretion after the first 20 minutes of rebreathing (15) . Care was taken to prevent loss of gas through leaks in the apparatus during each experiment. Furthermore, errors due to leakage would be expected to produce less consistent discrepancies between the results of the two methods than were actually found.
There is close quantitative agreement between these results in man and the observations of Root, Allen, and Gregersen in splenectomized dogs (18) . These investigators found the red cell volume of the splenectomized dog to be 12 per cent greater when measured with cells tagged with CO than with cells tagged with P82 (18) . On the other hand, Hevesy, Kbster, Sorensen, Warburg, and Zerahn (9) reported an even greater discrepancy (24 per cent) between cell volumes measured with CO and with P32-tagged cells. The procedures used by them, however, permitted errors tending to produce low values with the p82 method and high values with the CO method. These possible errors included: 1) Premature sampling when using P32 (5 to 10 minutes), whereas the CO samples were taken after a longer interval (15 minutes) ; and 2) use of a large rebreathing system.
No information is available as yet concerning the sites, presumably extravascular, where 12 to 16 per cent of the CO accumulates when introduced via the airways or by infusion of CO-tagged cells. According to Haldane and Smith (19) , dissolved CO in plasma and body fluid can account for not over 0.2 per cent of all the CO distributed throughout the body. The fact that equilibrium is reached within 20 minutes after delivery of the gas, after which the concentration of CO in the blood remains nearly constant (15) , suggests that the CO combines with compounds having an avidity for CO similar to that of hemoglobin. Experiments are in progress to determine the predominant sites of such combinations.
SUMMARY AND CONCLUSIONS
In 35 human subjects, 6 of whom were healthy and 29 suffering from a variety of diseases, simultaneous measurements were made of the apparent volume of red blood cells, using CO gas and cells tagged with Cr51. The volume of distribution of CO 20 minutes after delivery of the gas was found to be consistently larger than that of the radioactively tagged cells at an equal interval after injection. The mean difference amounted to 16 per cent of the volume as measured with Cr51-tagged cells. It is concluded that in this brief interval, significant quantities of CO leave the blood stream. The CO probably combines rapidly with compounds for which it has high affinity, but the sites where this occurs remain unknown.
Addendum: Recently we have found that better tagging of red cells with Cr51 is obtained when A.C.D. solution is used as anticoagulant instead of heparin during the in vitro handling of the blood.
